Advertisement

Thermo Fisher Scientific Inc.(NYSE: TMO) has signed a long-term license agreement with Japanese firm Fujirebio Inc. to make its test for the early detection of sepsis available on the Japanese firms laboratory instruments. Fujirebio’s Lumipulse product line of lab instruments is used in a significant number of hospitals and clinical reference labs in Japan and will be extended with future placements of Lumipulse platforms in other markets worldwide.

Advertisement
Advertisement